Shattuck Labs (STTK)
(Delayed Data from NSDQ)
$6.19 USD
-0.65 (-9.50%)
Updated Jun 14, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
STTK 6.19 -0.65(-9.50%)
Will STTK be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for STTK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STTK
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
STTK: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Shattuck Labs (STTK) a New Buy Stock
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Other News for STTK
Analysts Are Bullish on Top Healthcare Stocks: Vivani Medical (VANI), Shattuck Labs (STTK)
Shattuck gains on early-stage data update for lead asset in blood cancer
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Shattuck Labs Reports Promising Cancer Trial Outcomes
Shattuck Labs reports 'positive' interim data from Phase 1B trial of SL-172154